The spread, and end, of life-saving drugs
A clarion call has been sounded, mainly by insurance companies and generic drug manufacturers, and less so by consumers, to address the cost of prescription drugs.
The response: the McCain-Schumer Bill. By shortening the amount of time it takes for generic drugs to reach the marketplace, this bill would challenge the intellectual property rights of research-based pharmaceutical companies. McCain-Schumer also relaxes the rigorous Food and Drug Administration-imposed standard of bioequivalence, which requires a generic manufacturer to submit test results that confirm their generic...
Sorry, but comments are disabled for this article.